Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aduro names Gerald Chan to board

This article was originally published in Scrip

Executive Summary

Aduro BioTech, a clinical-stage biotechnology company, has named Dr Gerald Chan to its board of directors. Dr Chan is the co-founder of Morningside, a private investment group with venture, private equity and property investments. He currently serves on the boards of Advanced Cell Diagnostics, Oxyrane, Stealth Peptides, Synchroneuron, Apellis, Nucana, VTI and Matrivax. Furthermore, Dr Chan is a member of the Global Advisory Council of the International Society for Stem Cell Research, the Global Advisory Council of Harvard University, the Dean's Board of Advisors of the Harvard School of Public Health and the advisory boards of the Cold Spring Harbor Conferences Asia, the Johns Hopkins Nanjing Center, and the Columbia University Center for Radiological Research.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts